CL2023000121A1 - Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas - Google Patents

Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas

Info

Publication number
CL2023000121A1
CL2023000121A1 CL2023000121A CL2023000121A CL2023000121A1 CL 2023000121 A1 CL2023000121 A1 CL 2023000121A1 CL 2023000121 A CL2023000121 A CL 2023000121A CL 2023000121 A CL2023000121 A CL 2023000121A CL 2023000121 A1 CL2023000121 A1 CL 2023000121A1
Authority
CL
Chile
Prior art keywords
antibodies
treatment
neutrophilic dermatoses
neutrophilic
present
Prior art date
Application number
CL2023000121A
Other languages
English (en)
Inventor
Fine Jay
Lamar Janine
John Padula Steven
Ramanujam Meera
Visvanathan Sudha
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2023000121A1 publication Critical patent/CL2023000121A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para tratar, prevenir o mejorar una dermatosis neutrófila. Los métodos de la presente invención incluyen administrar a un paciente que tiene una dermatosis neutrófila una composición farmacéutica que incluye un anticuerpo contra el receptor de interleucina 36 (anti-IL-36R).
CL2023000121A 2020-07-17 2023-01-12 Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas CL2023000121A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063053129P 2020-07-17 2020-07-17

Publications (1)

Publication Number Publication Date
CL2023000121A1 true CL2023000121A1 (es) 2023-09-08

Family

ID=77265246

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000121A CL2023000121A1 (es) 2020-07-17 2023-01-12 Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas

Country Status (12)

Country Link
US (2) US12098207B2 (es)
EP (1) EP4182022A1 (es)
JP (1) JP7812364B2 (es)
KR (1) KR20230038774A (es)
CN (1) CN116745315A (es)
AU (1) AU2021309957A1 (es)
BR (1) BR112022026999A2 (es)
CA (1) CA3188382A1 (es)
CL (1) CL2023000121A1 (es)
MX (1) MX2023000763A (es)
TW (1) TW202225190A (es)
WO (1) WO2022015920A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020016738A2 (pt) 2018-03-14 2020-12-15 Boehringer Ingelheim International Gmbh Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada
EP4188441A1 (en) * 2020-07-30 2023-06-07 AnaptysBio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
WO2022150642A1 (en) * 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
TW202502379A (zh) * 2023-03-09 2025-01-16 德商百靈佳殷格翰國際股份有限公司 抗il-36r抗體用於治療化膿性汗腺炎（hs）之用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
EP1003861B1 (en) 1997-08-01 2006-10-04 Schering Corporation Mammalian cell membrane proteins; related reagents
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
EP1627927A3 (en) 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
AU2003282667A1 (en) 2002-10-03 2004-04-23 Large Scale Biology Corporation Multimeric protein engineering
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101389769A (zh) 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
WO2008033333A2 (en) 2006-09-08 2008-03-20 Amgen Inc. Il-1 family variants
WO2008133857A1 (en) 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
ES2540854T3 (es) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Usos de antagonistas MDL-1
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
EP2575884B1 (en) 2010-06-03 2018-07-18 AbbVie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
SI3536710T1 (sl) 2011-11-16 2026-04-30 Boehringer Ingelheim International Gmbh Protitelesa proti IL-36R
KR102063028B1 (ko) 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
WO2015022656A1 (en) 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN115925932A (zh) 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
CN106470162B (zh) 2015-08-19 2019-06-25 中国移动通信集团公司 一种业务报文的组播方法及装置
JP6654773B2 (ja) 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
BR112020016738A2 (pt) 2018-03-14 2020-12-15 Boehringer Ingelheim International Gmbh Uso de anticorpos anti-il-36r para o tratamento de psoríase pustular generalizada
JP2021517577A (ja) 2018-03-14 2021-07-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性腸疾患の処置のための抗ｉｌ−３６ｒ抗体の使用
HRP20240999T1 (hr) * 2018-07-16 2024-10-25 Regeneron Pharmaceuticals, Inc. Glodavački modeli bolesti ditra i njihova upotreba
AU2019306217B2 (en) 2018-07-16 2024-01-25 Regeneron Pharmaceuticals, Inc. Anti-IL36R antibodies
CA3120474A1 (en) 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
TW202037604A (zh) 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
IL286100B2 (en) * 2019-03-08 2024-12-01 Boehringer Ingelheim Int Anti-il-36r antibody formulations
CN115427439A (zh) 2019-10-30 2022-12-02 德克萨斯A&M大学系统 用于双靶标嵌合抗原受体t细胞疗法的蛋白酶开关
EP4334356A1 (en) * 2021-05-03 2024-03-13 Boehringer Ingelheim International Gmbh Method for producing spesolimab

Also Published As

Publication number Publication date
AU2021309957A1 (en) 2023-02-02
JP7812364B2 (ja) 2026-02-09
US20220073628A1 (en) 2022-03-10
MX2023000763A (es) 2023-02-13
US20240392019A1 (en) 2024-11-28
TW202225190A (zh) 2022-07-01
CA3188382A1 (en) 2022-01-20
CN116745315A (zh) 2023-09-12
KR20230038774A (ko) 2023-03-21
WO2022015920A1 (en) 2022-01-20
US12098207B2 (en) 2024-09-24
JP2023534955A (ja) 2023-08-15
EP4182022A1 (en) 2023-05-24
BR112022026999A2 (pt) 2023-01-24

Similar Documents

Publication Publication Date Title
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
PA8807801A1 (es) Inhibidores de cinesina como productos terapeuticos para el cancer
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
CL2025003481A1 (es) Anticuerpos anti-cd20 y estructuras car-t
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112022020643A2 (pt) Método de tratamento de esteato-hepatite não alcoólica
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
CL2022000091A1 (es) Métodos para tratar la pancreatitis. (divisional de solicitud n° 202100585)
CL2022002830A1 (es) Anticuerpo anti-ox40 y usos del mismo
BR112023026992A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
JOP20250015A1 (ar) تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
CL2021000892A1 (es) Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica
MX2022005245A (es) Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer.
MX2023005032A (es) Anticuerpos para tratamientos con opioides.
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
MX2024015160A (es) Metodos para el tratamiento de afecciones de perdida de sangre
MX2023013008A (es) Método para tratar cánceres de la sangre.